Avalon GloboCare (ALBT) Competitors $3.78 -0.05 (-1.31%) Closing price 03:59 PM EasternExtended Trading$3.84 +0.06 (+1.46%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. DARE, BCAB, QNTM, CLNN, CARA, GDTC, ENLV, CYTH, TPST, and TENXShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Daré Bioscience (DARE), BioAtla (BCAB), Quantum Biopharma (QNTM), Clene (CLNN), Cara Therapeutics (CARA), CytoMed Therapeutics (GDTC), Enlivex Therapeutics (ENLV), Cyclo Therapeutics (CYTH), Tempest Therapeutics (TPST), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Daré Bioscience BioAtla Quantum Biopharma Clene Cara Therapeutics CytoMed Therapeutics Enlivex Therapeutics Cyclo Therapeutics Tempest Therapeutics Tenax Therapeutics Daré Bioscience (NASDAQ:DARE) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Do insiders and institutionals have more ownership in DARE or ALBT? 6.7% of Daré Bioscience shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 4.0% of Daré Bioscience shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, DARE or ALBT? Avalon GloboCare has higher revenue and earnings than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaré Bioscience$9.78K2,614.11-$30.16M-$0.17-17.00Avalon GloboCare$1.37M5.23-$16.71M-$19.96-0.19 Does the MarketBeat Community believe in DARE or ALBT? Daré Bioscience received 358 more outperform votes than Avalon GloboCare when rated by MarketBeat users. CompanyUnderperformOutperformDaré BioscienceOutperform Votes35873.36% Underperform Votes13026.64% Avalon GloboCareN/AN/A Does the media prefer DARE or ALBT? In the previous week, Daré Bioscience had 6 more articles in the media than Avalon GloboCare. MarketBeat recorded 6 mentions for Daré Bioscience and 0 mentions for Avalon GloboCare. Daré Bioscience's average media sentiment score of 0.54 beat Avalon GloboCare's score of 0.00 indicating that Daré Bioscience is being referred to more favorably in the media. Company Overall Sentiment Daré Bioscience Positive Avalon GloboCare Neutral Which has more risk and volatility, DARE or ALBT? Daré Bioscience has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Do analysts recommend DARE or ALBT? Daré Bioscience presently has a consensus price target of $12.00, indicating a potential upside of 315.22%. Given Daré Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Daré Bioscience is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daré Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DARE or ALBT more profitable? Daré Bioscience has a net margin of -191.65% compared to Avalon GloboCare's net margin of -1,125.59%. Company Net Margins Return on Equity Return on Assets Daré Bioscience-191.65% N/A -18.98% Avalon GloboCare -1,125.59%N/A -73.69% SummaryDaré Bioscience beats Avalon GloboCare on 12 of the 16 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.16M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.1930.5026.8419.71Price / Sales5.23400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book-0.223.286.794.50Net Income-$16.71M-$72.17M$3.23B$248.18M7 Day Performance0.27%4.28%4.07%1.14%1 Month Performance17.03%7.62%12.52%15.20%1 Year Performance-10.95%-28.15%16.83%6.56% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare0.5526 of 5 stars$3.78-1.3%N/A-17.1%$7.16M$1.37M-0.195DAREDaré Bioscience1.4085 of 5 stars$2.88-1.0%$24.00+733.3%-60.5%$25.49M$9,784.00-4.8830BCABBioAtla2.0359 of 5 stars$0.43+0.6%$6.00+1,288.2%-84.0%$25.24M$11M-0.2560Gap UpQNTMQuantum BiopharmaN/A$9.12+0.6%N/AN/A$24.68MN/A-0.59N/ANews CoverageEarnings ReportCLNNClene2.5462 of 5 stars$2.72+3.4%$40.00+1,370.6%-65.1%$24.43M$342,000.00-0.52100CARACara Therapeutics1.2453 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeGDTCCytoMed Therapeutics1.596 of 5 stars$2.30+3.8%$5.00+117.0%-1.0%$24.29M$69,501.000.00N/AGap UpENLVEnlivex Therapeutics2.1018 of 5 stars$1.00-1.7%$10.00+897.0%-30.3%$23.72MN/A-1.0270News CoverageCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809TPSTTempest Therapeutics2.0047 of 5 stars$6.87+5.9%$30.00+336.7%-84.2%$23.72MN/A-4.4920Analyst RevisionTENXTenax Therapeutics2.089 of 5 stars$5.71+2.5%$18.00+215.2%+60.0%$23.69MN/A-1.079News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies Daré Bioscience Competitors BioAtla Competitors Quantum Biopharma Competitors Clene Competitors Cara Therapeutics Competitors CytoMed Therapeutics Competitors Enlivex Therapeutics Competitors Cyclo Therapeutics Competitors Tempest Therapeutics Competitors Tenax Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALBT Stock Free ALBT Stock Alerts